Adc Therapeutics Sa Stock Alpha and Beta Analysis

ADCT Stock  USD 1.85  0.08  4.52%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as ADC Therapeutics SA. It also helps investors analyze the systematic and unsystematic risks associated with investing in ADC Therapeutics over a specified time horizon. Remember, high ADC Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to ADC Therapeutics' market risk premium analysis include:
Beta
0.76
Alpha
0.47
Risk
5.3
Sharpe Ratio
0.0018
Expected Return
0.0095
Please note that although ADC Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, ADC Therapeutics did 0.47  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of ADC Therapeutics SA stock's relative risk over its benchmark. ADC Therapeutics has a beta of 0.76  . As returns on the market increase, ADC Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding ADC Therapeutics is expected to be smaller as well. At this time, ADC Therapeutics' Enterprise Value Over EBITDA is comparatively stable compared to the past year. Enterprise Value Multiple is likely to gain to 0.12 in 2025, despite the fact that Book Value Per Share is likely to grow to (1.98).

Enterprise Value

(20.3 Million)

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out ADC Therapeutics Backtesting, ADC Therapeutics Valuation, ADC Therapeutics Correlation, ADC Therapeutics Hype Analysis, ADC Therapeutics Volatility, ADC Therapeutics History and analyze ADC Therapeutics Performance.

ADC Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. ADC Therapeutics market risk premium is the additional return an investor will receive from holding ADC Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ADC Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate ADC Therapeutics' performance over market.
α0.47   β0.76

ADC Therapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of ADC Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how ADC Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

ADC Therapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how ADC Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading ADC Therapeutics shares will generate the highest return on investment. By understating and applying ADC Therapeutics stock market price indicators, traders can identify ADC Therapeutics position entry and exit signals to maximize returns.

ADC Therapeutics Return and Market Media

The median price of ADC Therapeutics for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 1.76 with a coefficient of variation of 19.5. The daily time series for the period is distributed with a sample standard deviation of 0.36, arithmetic mean of 1.85, and mean deviation of 0.22. The Stock received a lot of media exposure during the period.
 Price Growth (%)  
       Timeline  
1
Acquisition by Redmile Group, Llc of 50000 shares of ADC Therapeutics at 2.1148 subject to Rule 16b-3
12/17/2024
2
Disposition of 44996 shares by Redmile Group, Llc of ADC Therapeutics at 1.633 subject to Rule 16b-3
12/18/2024
3
ADC Therapeutics stock rises on enrollment update
12/31/2024
4
HC Wainwright Reiterates Buy Rating for ADC Therapeutics - MarketBeat
01/06/2025
5
Growing Focus on ADC Therapeutics
01/21/2025
6
Disposition of 31000 shares by Azelby Robert of ADC Therapeutics at 2.29 subject to Rule 16b-3
01/23/2025
7
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
01/30/2025
8
Discretionary transaction by Redmile Group, Llc of 20000 shares of ADC Therapeutics at 4.4099 subject to Rule 16b-3
01/31/2025
9
BlackRock, Inc.s Strategic Acquisition of ADC Therapeutics SA Shares
02/04/2025
10
Acquisition by Mallik Ameet of 650000 shares of ADC Therapeutics at 1.61 subject to Rule 16b-3
02/13/2025
11
Acquisition by Redmile Group, Llc of 150000 shares of ADC Therapeutics at 3.0824 subject to Rule 16b-3
02/14/2025
12
Discretionary transaction by Redmile Group, Llc of 37429 shares of ADC Therapeutics at 1.7075 subject to Rule 16b-3
02/25/2025
13
Acquisition by Redmile Group, Llc of 100000 shares of ADC Therapeutics at 2.4879 subject to Rule 16b-3
02/26/2025
14
Tango Therapeutics, Inc. Reports Q4 Loss, Lags Revenue Estimates
02/27/2025
15
Discretionary transaction by Redmile Group, Llc of 108844 shares of ADC Therapeutics at 2.16 subject to Rule 16b-3
02/28/2025
16
Discretionary transaction by Redmile Group, Llc of 1259822 shares of ADC Therapeutics at 3.25 subject to Rule 16b-3
03/06/2025
17
ADC THERAPEUTICS SA -REDH Earnings Preview Recent ADCT Insider Trading, Hedge Fund Activity, and More - Nasdaq
03/11/2025

About ADC Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including ADC or other stocks. Alpha measures the amount that position in ADC Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2023 2024 2025 (projected)
Payables Turnover0.160.190.18
Days Of Inventory On Hand2.3K2.1K2.2K

ADC Therapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of ADC Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ADC Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of ADC Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of ADC Therapeutics. Please utilize our Beneish M Score to check the likelihood of ADC Therapeutics' management manipulating its earnings.
27th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with ADC Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for ADC Stock Analysis

When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.